These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23509108)

  • 1. Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial.
    Udell JA; Morrow DA; Braunwald E; Swedberg K; Bode C; Rifai N; Brunel PC; Prescott MF; Ren F; Hoffman EB; Scirica BM
    Clin Chem; 2013 Jun; 59(6):959-67. PubMed ID: 23509108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial.
    Scirica BM; Morrow DA; Bode C; Ruzyllo W; Ruda M; Oude Ophuis AJ; Lopez-Sendon J; Swedberg K; Ogorek M; Rifai N; Lukashevich V; Maboudian M; Cannon CP; McCabe CH; Braunwald E
    Eur Heart J; 2010 Aug; 31(16):1993-2005. PubMed ID: 20558431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of the renin system by aliskiren and valsartan.
    Birkenhäger WH; Staessen JA
    Lancet; 2007 Jul; 370(9583):195-196. PubMed ID: 17658374
    [No Abstract]   [Full Text] [Related]  

  • 4. Aliskiren improves left ventricular dysfunction and reduces cardiac dilation in Syrian cardiomyopathic hamsters.
    Crespo MJ; Cangiano JL; Altieri PI; Escobales N
    J Cardiovasc Pharmacol; 2012 Jun; 59(6):547-52. PubMed ID: 22370958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
    Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
    Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy.
    Bomback AS; Rekhtman Y; Klemmer PJ; Canetta PA; Radhakrishnan J; Appel GB
    J Am Soc Hypertens; 2012; 6(5):338-45. PubMed ID: 22995802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
    Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF)].
    Skvortsov AA; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Mareev VIu; Belenkov IuN
    Ter Arkh; 2005; 77(8):34-43. PubMed ID: 16206603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of renin-angiotensin-aldosterone system blockade on chlorhexidine gluconate-induced sclerosing encapsulated peritonitis in rats.
    Koçak G; Azak A; Astarcı HM; Huddam B; Karaca G; Ceri M; Can M; Sert M; Duranay M
    Ther Apher Dial; 2012 Feb; 16(1):75-80. PubMed ID: 22248199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
    Higashikuni Y; Takaoka M; Iwata H; Tanaka K; Hirata Y; Nagai R; Sata M
    Hypertens Res; 2012 Jan; 35(1):62-9. PubMed ID: 21833001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
    Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
    Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels.
    Gant CM; Laverman GD; Vogt L; Slagman MCJ; Heerspink HJL; Waanders F; Hemmelder MH; Navis G;
    BMC Nephrol; 2017 Dec; 18(1):370. PubMed ID: 29262813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
    Azizi M; Ménard J; Bissery A; Guyenne TT; Bura-Rivière A; Vaidyanathan S; Camisasca RP
    J Am Soc Nephrol; 2004 Dec; 15(12):3126-33. PubMed ID: 15579516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.
    Whaley-Connell A; Habibi J; Nistala R; Hayden MR; Pulakat L; Sinak C; Locher B; Ferrario CM; Sowers JR
    Regul Pept; 2012 Jun; 176(1-3):36-44. PubMed ID: 22465166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise.
    Williams B; Baschiera F; Lacy PS; Botha J; Prescott MF; Brunel P
    J Renin Angiotensin Aldosterone Syst; 2013 Mar; 14(1):56-66. PubMed ID: 22859712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    Pfeffer MA
    Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination angiotensin converting enzyme and direct renin inhibition in heart failure following experimental myocardial infarction.
    Connelly KA; Advani A; Advani S; Zhang Y; Thai K; Thomas S; Krum H; Kelly DJ; Gilbert RE
    Cardiovasc Ther; 2013 Apr; 31(2):84-91. PubMed ID: 21884026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.
    Whaley-Connell A; Habibi J; Rehmer N; Ardhanari S; Hayden MR; Pulakat L; Krueger C; Ferrario CM; DeMarco VG; Sowers JR
    Metabolism; 2013 Jun; 62(6):861-72. PubMed ID: 23352204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study.
    Krum H; Massie B; Abraham WT; Dickstein K; Kober L; McMurray JJ; Desai A; Gimpelewicz C; Kandra A; Reimund B; Rattunde H; Armbrecht J;
    Eur J Heart Fail; 2011 Jan; 13(1):107-14. PubMed ID: 21169387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases].
    Dralova OV; Maksimov ML; Derbentseva EA; Ermolaeva AS; Starodubtsev AK
    Eksp Klin Farmakol; 2011; 74(4):14-7. PubMed ID: 21678653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.